Healthcare
from24/7 Wall St.
1 day agoJosh Brown: Biotech growth stocks immune to disruption risk
Large-cap biotech companies resist overnight AI-style disruption due to lengthy FDA approval processes, but face distinct slow-motion threats from patent cliffs, biosimilar competition, and drug pricing reform.